ClinicalTrials.gg
Status unknownNCT01683474Venus-AUpdated Jan 6, 2015

Safety and Performance of TAVI of Venus MedTech Aortic Valve Prosthesis

An interventional study of Venus MedTech Aortic Valve Prosthesis in Aortic Valve Stenosis and Aortic Valve Calcification, sponsored by Venus MedTech (HangZhou) Inc.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-06.

Sponsored by Venus MedTech (HangZhou) Inc. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
31st of 47
80 · median 120
Started
2012
the only one that year
No phase
37 of 69
20 open now
Registered
1st of 69
by date

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 31st largest by planned enrollment of the 47 interventional ones that give a count, is the only one that started in 2012, is one of 37 with no phase, and was the 1st registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

  1. objectives

    • Evaluate the performance of Venus MedTech aortic valve prosthesis intervention by femoral artery
    • Evaluate safety and clinical benefit of percutaneous implantation of the Venue MedTech aortic valve prosthesis.
    • Continuous observe 12 months of safety and efficacy.
  2. Approximately 80 patients presenting with native aortic valve stenosis necessitating valve replacement which are considered unsuitable for Surgical Valve Replacement, with a high surgical risk, as attested to by both the surgeon and the cardiologist are recruited in the study.
  3. Safety and performance will be evaluated at discharge and at 30 days post procedure. Valve safety, performance and placement will be followed up at 6 and 12 months post-procedure.
Read the detailed description

A prospective OPC study to evaluate its performance and long-term safety and effectiveness of Venus-A aortic valve.

03

Conditions studied

  • Aortic Valve Stenosis
  • Aortic Valve Calcification

Keywords

  • aortic valve stenosis
  • Calcification
  • TAVI
  • aortic valve Prosthesis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient ≥ 40 mm Hg, or jet velocity ≥ 4.0 m/s, or an aortic valve area (AVA) of \< 0.8 cm2 (or AVA index \< 0.5 cm2/m2)
  • Symptomatic due to aortic valve stenosis as demonstrated by Functional Class ≥ II
  • The subject or the subject's legal representative was informed of the nature of the study, agreed to its provisions and provided written as approved by the Institutional Review Board of the respective clinical site.
  • The subject agreed to comply follow-up evaluation
  • is evaluated by at least one cardiologist and two cardiovascular surgeon, and they agreed that medical factors precluding operation suitable for surgery (the probability of death or serious, irreversible morbidity exceeded 50%)
  • STS score ≥ 10%

Exclusion criteria

Exclusion Criteria:

  • Patient refuses aortic valve replacement surgery.
  • Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].
  • Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.
  • Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+).
  • Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days (6 month if DES implant)
  • Implanted any heart valve prosthesis, prosthetic valve ring, severe mitral valve ring calcification (MAC), severe(>3+)mitral valve insufficiency, or Gorelin symptom
  • Blood dyscrasia such as leukopenia (WBC \< 3×109/L), acute anemia ( \< 90 g/L), thrombocytopenia ( \< 50×109/L), bleeding diathesis, or history of coagulopathy.
  • Untreated coronary artery disease requiring revascularization
  • Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support devices
  • Need for emergency surgery for any reason
  • Hypertrophic cardiomyopathy with or without obstruction (HOCM)
  • Severe ventricular dysfunction with \< 20%
  • Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months
  • A known or to aspirin, heparin, ticlopidine, clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated.
  • Native aortic annulus size \< 20 mm or> 29 mm as measured by echocardiogram.
  • Cerebrovascular Accident (CVA) within 6 months, including .
  • Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis.
  • \< 12 months
  • Significant abdominal or thoracic aorta disease, including aneurysm (defined as maximal luminal diameter 5cm or greater), marked tortuosity (hyperacute bend), aortic arch atheroma (especially if thick [> 5 mm], protruding or ulcerated), narrowing of the abdominal aorta (especially with calcification and surface irregularities), or severe "unfolding" and tortuosity of the thoracic aorta
  • Iliofemoral vessel characteristics that would preclude safe placement of 16F or 18F introducer sheath such as severe obstructive calcification, severe tortuosity or vessel size diameter \< 7 mm.
  • Currently participating in an drug or another device study.
  • Active bacterial endocarditis or other active infections.
  • Bulky calcified aortic valve leaflets in close proximity to coronary ostia
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Venus A-Valve

    single arm with intervention that percutaneous implantation of the Venus MedTech Aortic Valve Prosthesis

    Device: Venus MedTech Aortic Valve Prosthesis

Interventions

  • DeviceVenus MedTech Aortic Valve Prosthesis

    Percutaneous implantation of aortic valve of Venus-A

    Also known as: Venus A-Valve, Venus A-Valve System

06

What researchers measure

Primary outcomes

  1. All cause mortality and major stroke at 12 months post-procedure.

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Valve performance and placement at 6 and 12 months post-procedure

    Time frame: 6 and 12 months post-procedure

07

Study locations

1 of 1 sites recruiting
  • Fu Wai Hospital, CAMS & PUMA
    Beijing, Beijing 100037, China
    Recruiting
08

References and documents

Publications

  • Lei WH, Liao YB, Wang ZJ, Ou YW, Tsauo JY, Li YJ, Xiong TY, Zhao ZG, Wei X, Meng W, Feng Y, Chen M. Transcatheter Aortic Valve Replacement in Patients with Aortic Stenosis Having Coronary Cusp Fusion versus Mixed Cusp Fusion Nonraphe Bicuspid Aortic Valve. J Interv Cardiol. 2019 Nov 3;2019:7348964. doi: 10.1155/2019/7348964. eCollection 2019. PubMed 31777470 ↗
  • Liao YB, Li YJ, Xiong TY, Ou YW, Lv WY, He JL, Li YM, Zhao ZG, Wei X, Xu YN, Feng Y, Chen M. Comparison of procedural, clinical and valve performance results of transcatheter aortic valve replacement in patients with bicuspid versus tricuspid aortic stenosis. Int J Cardiol. 2018 Mar 1;254:69-74. doi: 10.1016/j.ijcard.2017.12.013. Epub 2017 Dec 9. PubMed 29246428 ↗
  • Jilaihawi H, Wu Y, Yang Y, Xu L, Chen M, Wang J, Kong X, Zhang R, Wang M, Lv B, Wang W, Xu B, Makkar RR, Sievert H, Gao R. Morphological characteristics of severe aortic stenosis in China: imaging corelab observations from the first Chinese transcatheter aortic valve trial. Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:752-61. doi: 10.1002/ccd.25863. Epub 2015 Feb 19. PubMed 25630494 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Feb 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 11, 2012
Start
Sep 2012
Primary completionEst.
Feb 2016
CompletionEst.
Apr 2016
Last update
Jan 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01683474
Lead sponsor
Venus MedTech (HangZhou) Inc.
Responsible party
Sponsor
First posted
Sep 11, 2012
Start date
Sep 2012
Primary completion
Feb 2016 (estimated)
Completion
Apr 2016 (estimated)
Last update
Jan 6, 2015

Study contacts

Runlin Gao, MD
Contact
gaorunlin4study@gmail.com
88398866 ext. 8266
Ruilin Gao, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion